A Phase 1 interventional study of tucatinib and itraconazole in Drug-drug Interaction, sponsored by Seagen Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-18.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being done to look at how tucatinib could affect the way other drugs work. This study will look at healthy volunteers and how tucatinib affects their liver enzymes. Liver enzymes can change how drugs work in the body. There are 5 parts to this study. Parts A and C are looking at how the body breaks down tucatinib when there are lower levels of certain liver enzymes. Part B is looking at how the body breaks down tucatinib when there are high levels of certain liver and stomach enzymes. Parts D and E are looking at how tucatinib could change the levels of some liver and stomach enzymes in the body. This will help us know more about how tucatinib should be given to patients.
This is a fixed-sequence, drug-drug interaction study of tucatinib conducted in 5 parts in healthy subjects. Part A will evaluate the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) of tucatinib. Part B will evaluate the effect of rifampin, a strong inducer of CYP3A4 and CYP2C8, on the PK of tucatinib. Part C will evaluate the effect of the strong CYP2C8 inhibitor gemfibrozil on the PK of tucatinib. Part D will evaluate the effects of tucatinib on the PK of substrate probes of the metabolizing enzymes CYP2C8 (repaglinide), CYP2C9 (tolbutamide), and CYP3A4 (midazolam). Part E will evaluate the effect of tucatinib on the PK of a substrate probe of the transporter P-gp (digoxin). Parts A, B, C, D, and E of the study are independent of one another and do not need to be conducted in a particular order.
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
First submitted before Seagen Inc. became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tucatinib plus Itraconazole
Drug: tucatinib · Drug: itraconazole
Tucatinib plus Rifampin
Drug: tucatinib · Drug: rifampin
Tucatinib plus Gemfibrozil
Drug: tucatinib · Drug: gemfibrozil
Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
Drug: tucatinib · Drug: repaglinide · Drug: tolbutamide · Drug: midazolam
Tucatinib plus Digoxin
Drug: tucatinib · Drug: digoxin
300mg dose, orally administered
200mg dose
600mg dose
600mg tablets
1mg dose
500mg dose
2mg dose
0.5 mg dose
Area under the concentration-time curve (AUC) from time 0 to infinity
PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)
Time frame: Up to 22 days
AUC from time 0 to the time of the last quantifiable concentration
PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)
Time frame: Up to 22 days
Percentage extrapolation in AUC
PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)
Time frame: Up to 22 days
Maximum observed concentration
PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)
Time frame: Up to 22 days
Time of maximum observed concentration
PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)
Time frame: Up to 22 days
Apparent terminal elimination half-life
PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)
Time frame: Up to 22 days
Apparent total clearance
PK parameters for tucatinib (Parts A, B, and C); repaglinide (Part D), tolbutamide (Part D), midazolam (Part D), and digoxin (Part E).
Time frame: Up to 22 days
Apparent volume of distribution
PK parameters for tucatinib (Parts A, B, and C); repaglinide (Part D), tolbutamide (Part D), midazolam (Part D), and digoxin (Part E).
Time frame: Up to 22 days
Metabolite-to-parent ratio based on AUC
PK parameters for M4 metabolite, 4-hydroxytolbutamide metabolite, and 1-hydroxymidazolam metabolite (Part D only)
Time frame: Up to 22 days
Incidence of adverse events (AEs)
Parts A, B, C, D, and E (all)
Time frame: Up to 58 days
Incidence of laboratory abnormalities
Parts A, B, C, D, and E (all)
Time frame: Up to 58 days
12-lead electrocardiogram (ECG) assessment
PR, RR, QRS, and QT interval. Parts A, B, C, D, and E (all)
Time frame: Up to 58 days
Vital signs measurements
Oral temperature. Parts A, B, C, D, and E (all)
Time frame: Up to 58 days
Vital signs measurements
Respiratory rate. Parts A, B, C, D, and E (all)
Time frame: Up to 58 days
Vital signs measurements
Blood pressure (systolic and diastolic). Parts A, B, C, D, and E (all)
Time frame: Up to 58 days
Vital signs measurements
Heart rate. Parts A, B, C, D, and E (all)
Time frame: Up to 58 days
Physical examinations
Incidence of AEs resulting from clinically significant findings in examination of general appearance, skin, thorax/lungs, cardiovascular system, and abdomen. Parts A, B, C, D, and E (all)
Time frame: Up to 58 days
AUC within a dosing interval
PK parameters of tucatinib and ONT-993; Parts D and E only
Time frame: Up to 15 days
AUC from time 0 to infinity
PK parameters of tucatinib and ONT-993; Parts D and E only
Time frame: Up to 8 days
AUC from time 0 to the time of the last quantifiable concentration
PK parameters of tucatinib and ONT-993; Parts D and E only
Time frame: Up to 15 days
Percentage extrapolation in AUC
PK parameters of tucatinib and ONT-993; Parts D and E only
Time frame: Up to 15 days
Maximum observed concentration
PK parameters of tucatinib and ONT-993; Parts D and E only
Time frame: Up to 15 days
Time of maximum observed concentration
PK parameters of tucatinib and ONT-993; Parts D and E only
Time frame: Up to 15 days
Apparent terminal elimination half-life
PK parameters of tucatinib and ONT-993; Parts D and E only
Time frame: Up to 15 days
Apparent total clearance
PK parameter of tucatinib; Parts D and E only
Time frame: Up to 8 days
Apparent total clearance at steady state
PK parameter of tucatinib; Parts D and E only
Time frame: Up to 15 days
Apparent volume of distribution
PK parameter of tucatinib; Parts D and E only
Time frame: Up to 8 days
Apparent volume of distribution at steady state
PK parameter of tucatinib; Parts D and E only
Time frame: Up to 15 days
Accumulation ratio
PK parameters of tucatinib and ONT-993; Parts D and E only
Time frame: Up to 15 days
Metabolite-to-parent ratio based on AUC
PK parameter of ONT-993; Parts D and E only
Time frame: Up to 15 days
Ran from Sep 2018 to primary completion in Dec 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tucatinib